Contact this trialFirst, we need to learn more about you.
RNAi Therapeutics
Vutrisiran vs Patisiran for Amyloidosis
Recruiting2 awardsPhase 3
La Mesa, California
This trial is studying vutrisiran, which is given as a shot under the skin, to see how well it works compared to patisiran, which is given as a drip into a vein, for people with hereditary ATTR amyloidosis. People will get vutrisiran or patisiran once every 3 months or 3 weeks, respectively, for 18 months. The trial will use the placebo arm of the APOLLO study as an external comparator for the primary and most other efficacy endpoints during the 18 Month Treatment Period. Following the 18 Month Treatment Period, all participants will be randomized to receive
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.